 | Up a level |
2018
Moesges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G. and Shamji, M. H. (2018). A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy, 73 (4). S. 896 - 905. HOBOKEN: WILEY. ISSN 1398-9995
2016
Zadoyan, G., V, Allekotte, S., Shamji, M. H., Kasche, E. M., Singh, J., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Legon, T., Caplanusi, A., Durham, S. R. and Mosges, R. (2016). Immunological biomarker predict clinical effects in subcutaneous peptide allergen immunotherapy. Allergy, 71. S. 319 - 321. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995
2015
Shamji, M. H., Kasche, E. M., Zadoyan, G., Astvatsourov, A., Durham, S. R., Pirotton, S., Legon, T. and Moesges, R. (2015). Hydrolyzed Lolium perenne peptide fragments administered subcutaneously to hay fever patients induce allergen-specific IgG(4) and blocking antibodies after two or more weeks of treatment. Allergy, 70. S. 631 - 633. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995